Topics

Articles

Like the other war on drugs, there's no end in sight

The war on prescription drug abuse

When drugs in development today hit the marketplace in 2020, they will need evidence of economic and clinical value results to be commercially successful

Pharma's stake in comparative effectiveness research

Pharmaceutical marketing is now operating in a new landscape--the Economy of Attention

Liberating time in the Economy of Attention

Abbott's spinout of AbbVie offers lessons

Tomorrow's biopharma industry: new biotech products or higher operational efficiency--or both?

Another go at medication adherence

Applying the managed services model to commercial operations can result in dramatic savings as pharma companies globalize

A managed services approach to sales and marketing

BeSafeRx: FDA helping consumers avoid risks of  online prescription drug purchases

The USP  standard, currently in draft form, is an effort to provide recommendations for end-to-end supply chain integrity

Complex supply chains demand a holistic approach to protect patients

In the evolving world of pharma compliance, The PDMA Sharing Conference provides answers

Industry is not waiting for action in Washington

Opinion